Erratum to the References in Publication 98, (Volume 35, Issue 3)

Article Outline

• References
• Copyright

The Publisher would like to point out that the last page of the references were omitted from the PDF and printed versions of the above publication. They are reproduced in full below:

Back to Article Outline

References 

Ankem, M.K., De Carvalho, V.S., Harangozo, A.H., et al., 2002. Implications of radioactive seed migration to the lungs after prostate brachytherapy. Urology 59, 555–559.

Aronowitz, J.N., 2002. Dawn of prostate brachytherapy: 1915–1930, Int. J. Radiat. Oncol. Biol. Phys. 54, 712–718.

Brenner, D.J., Curtis, R.E., Hall, E.J., et al., 2000. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery, Cancer 88, 398–406.

Buron, C., Chauveinc, L., Salem, N., et al., 2004. An economic evaluation of interstitial brachytherapy, radical prostatectomy and external beam radiotherapy for localized prostate cancer: results during the first year after therapy, Radiother. Oncol. 71 (Suppl. 2), S86.

Chauveinc, L., Osseli, A., Flam, T., et al., 2004. Migration des grains d’iode 125 après curiethérapie prostatique: étude d’une série de 170 patients, Cancer/Radiothérapie 8, 211–216.

Dauer, L.T., Zelefsky, M., Horan, C., et al., 2004. Assessment of radiation safety instructions to patients based on measured dose rates following prostate brachytherapy, Brachytherapy 3, 1–6.

Eckerman, K.F., Thompson, E.A., Veinot, K.G. Dose Coefficient for Deterministic Health Effects. ORNL/TM-2003/196. Oak Ridge National Laboratory, Oak Ridge, USA (in press).

Eshleman, J.S., Davis, B.J., Pisansky T.M., et al., 2004. Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration, Int. J. Radiat. Oncol. Biol. Phys. 59, 419–425.

French Decree No. 2002-460, 2002. Journal Officiel de la République Française.

Grimm, P.D., Blasko, J., Ragde, H., et al., 1993. Migration of iodine-125 and palladium-103 seeds to the lung after transperineal brachytherapy for prostate cancer, Endocurie/Hypertherm. Oncol. 9, 90.

Grimm, P.D., Blasko, J.C., Sylvester, J.E., et al., 2001. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy, Int. J. Radiat. Oncol. Biol. Phys. 51, 31–40.

Hilaris, B.S., Batata, M.E., Anderson, L.L., 1987. Chapter 26. In: Pierquin, B., Wilson, J.F., Chassagne, D. (Eds.), Prostate in Modern Brachytherapy, Masson, New York, pp. 234–247.

IAEA, 1996. BSS Safety Series No. 115. Food and Agriculture Organization of the United Nations, International Atomic Energy Agency, International Labour Organization, OECD Nuclear Energy Agency, Pan American Health Organization, World Health Organization, Vienna.

IAEA, 2002a. Prevention of the Inadvertent Movement and Illicit Trafficking of Radioactive Materials. TECDOC-1311. International Atomic Energy Agency, Vienna.

IAEA, 2002b. Advisory Material for the IAEA Regulations for the Safe Transport of Radioactive Materials. Safety Standards Series No. TS-G.1.1. International Atomic Energy Agency, Vienna.

IAEA, 2003. Method for Developing Arrangements for Response to a Nuclear or Radiological Emergency. EPR-METHOD. International Atomic Energy Agency, Vienna.

ICRP, 1977. Recommendations of the International Commission on Radiological Protection. ICRP Publication 26, Ann. ICRP.

ICRP, 1991. 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60, Ann. ICRP 21(1–3).

ICRP, 1996. Radiological protection and safety in medicine. ICRP Publication 73, Ann. ICRP 26.

ICRP, 2001. Prevention of accidental exposures to patients undergoing radiation therapy. ICRP Publication 86, Ann. ICRP 30 (3).

ICRP, 2005a. Development of the Draft 2005 Recommendations of the ICRP: a collection of papers. ICRP Supporting Guidance 4, Ann. ICRP 34 (Suppl).

ICRP, 2005b. Prevention of high-dose-rate brachytherapy accidents. ICRP Publication 97, Ann. ICRP 35 (3).

ICRU, 1992. Measurement of Dose Equivalents from External Radiation Sources – Part 2. ICRU Report No. 47. International Commission on Radiation Units and Measurement, Bethesda, MD.

IRSN, 2003. Report SDOS 2003-009. Institut de Radioprotection et de Sûreté Nucléaire.

Japanese Society for Therapeutic Radiology and Oncology, Japanese Urological Association and Japan Radiological Society, 2003. Guidelines for Safety Control of Brachytherapy with Permanently Implanted Sealed Seed Radiation Sources for Prostate Cancer. Japan Radioisotope Association, Tokyo. In Japanese.

Johnstone, P.A., Powell, C.R., Riffenburgh, R., Rohde, D.C., Kane, C.J., et al., 1998. Second primary malignancies in T1-3N0 prostate cancer patients treated with radiation therapy with 10-year followup, J. Urol. 159, 946–949.

Kleinerman, R.A., Liebermann, J.V., Li, F.P., 1985. Second cancer following cancer of the male genital system in Connecticut, 1935–1982, Natl. Cancer Inst. Monogr. 68, 139–147.

Kollmeier, M.A., Stock, R.G., Stone, N., 2003. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality, Int. J. Radiat. Oncol. Biol. Phys. 57, 645–653.

Kupelian, P.A., Potters, L., Khuntia, D., et al., 2004. Radical prostatectomy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer, Int. J. Radiat. Oncol. Biol. Phys. 58, 25–33.

Langley, S.E., Laing, R.W., 2004. Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancer. Prostate Cancer Prostatic Dis.

Levi, F., Randimbison, L., Te, V.C., et al., 1999. Second primary tumors after prostate carcinoma, Cancer 86, 1567–1570.

Marchese, M.J., Nori, D., Anderson, L.L., et al., 1984. A versatile permanent planar implant technique utilizing iodine-125 seeds imbedded in gelfoam, Int. J. Radiat. Oncol. Biol. Phys. 10, 747–751.

Merrick, G.S., Bulter, W.M., Dorsey, A.T., et al., 2000. Seed fixity in the prostate/periprostatic region following brachytherapy, Int. J. Radiat. Oncol. Phys. 46, 215–220.

Michalski, J., Mutic, S., Eichling, J., Ahmed, S.N., 2003. Radiation exposure to family and household members after prostate brachytherapy, Int. J. Radiat. Oncol. Biol. Phys. 56, 764–768.

Miller, V.A., Reuter, V., Scaer, H.I., 1995. Primary squamous cell carcinoma of the prostate after radiation seed implantation for adenocarcinoma, Urology 46, 111–113.

Movsas, B., Hanlon, A.L., Pinover, W., et al., 1998. Is there an increased risk of second primaries following prostate cancer irradiation? Int. J. Radiat. Oncol. Biol. Phys. 41, 251–255.

Mydlo, J., Lebed, B., 2004. Does brachytherapy of the prostate affect sperm quality and/or fertility in younger men? Scand. J. Urol. Nephrol. 38, 221–224.

Nag, S., Scaperoth, D.D., Badalement, R., et al., 1995. Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration, Urology 45, 87–92.

Nag, S., Singavajhala, V., Martinez-Monge, R., 1997. Pulmonary embolization of permanently implanted radioactive palladium-103 seeds for carcinoma of the prostate, Int. J. Radiat. Oncol. Biol. Phys. 39, 667–670.

Nath, R., Anderson, L.L., Meli, J.A., et al., 1997. Cremated remains should not be scattered in the environment until a minimum of ten half-lives has elapsed from the date of the implant (AAPM TG-56), Med. Phys. 24, 1557–1598.

NCRP, 1970. Precautions in the Management of Patients who have Received Therapeutic Amounts of Radionuclides. NCRP Report No. 37. National Council on Radiation Protection and Measurements, Bethesda, MD.

NCRP, 1995. Use of Personal Monitors to Estimate Effective Dose Equivalent and Effective Dose to Workers for External Exposure to Low-LET Radiation. NCRP Report No. 122. National Council on Radiation Protection and Measurements, Bethesda, MD.

NCRP, 1996. Screening Models for Releases of Radionuclides to Atmosphere, Surface Water, and Ground. NCRP Report No. 123. National Council on Radiation Protection and Measurements, Bethesda, MD.

Neugut, A.I., Ahsan, H., Robinson, E., et al., 1997. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma, Cancer 79, 1600–1604.

Older, R.A., Synder, B., Krupski, T.L., et al., 2001. Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy, J. Urol. 165, 1590–1592.

Osterlind, A., Roth, M., Prener, A., 1985. Second cancer following cancer of the male genital system in Danmark, 1943–1980, Natl. Cancer Inst. Monogr. 68, 341–347.

Pasteau, O., Degrais, P., 1913. De l’emploi du radium dans les cancers de la prostate, J. Urol. (Paris) 4, 341–345.

Pickles, T., Phillips, N., 2002. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984–2000, Radiother. Oncol. 65, 145–151.

Potters, L., Klein, E.A., Kattan, M.W., et al., 2004, Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation, Radiother. Oncol. 71, 29–33.

Que, W., 2001. Radiation safety issues regarding the cremation of the body of a ¹²⁵I prostate implant patient, J. Appl. Med. Phys. 2, 174–177.

Ragde, H., Korb, L.J., Elgamal, A.A., et al., 2000. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up, Cancer 89, 135–141.

Rivard, M.J., Coursey, B.M., Dewerd, L.A., et al., 2004. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations, Med. Phys. 31, 633–674.

Smathers, S., Wallner, K., Korssjoew, T., et al., 1999. Radiation safety parameters following prostate brachytherapy, Int. J. Radiat. Oncol. Biol. Phys. 45, 397–399.

Steinfeld, A.D., Donahuue, B.R., Plaine, L., 1991. Pulmonary embolization of iodine-125 seeds following prostate implantation, Urology 37, 149–150.

Stone, N.N., Stock, R.G., 2002. Permanent seed implantation for localized adenocarcinoma of the prostate, Curr. Urol. Rep. 3, 201–206.

Stutz, M., Petrikas, J., Raslowsky, M., et al., 2003. Seed loss through the urinary tract after prostate brachytherapy: examining the role of cystoscopy and straining post-implant, Med. Phys. 30, 2695–2698.

Sylvester, J.E., Blasko, J.C., Grimm, P.D., et al., 2004. Prostate cancer patients treated with external beam radiation therapy combined with ¹²⁵I/¹⁰³Pd brachytherapy: Seattle fifteen year outcome results, Radiother. Oncol. 71 (Suppl. 2), S17.

Sylvester, J.E., Blasko, J.C., Grimm, P.D., et al., 2004. Fifteen year follow up of the first cohort of localized prostate cancer patients treated with brachytherapy, J. Clin. Oncol. 22, 14S 398S.

Tapen, E.M., Blasko, J.C., Grimm, P.D., et al., 1998. Reduction of radioactive seed embolization to the lung following prostate brachytherapy, Int. J. Radiat. Oncol. Biol. Phys. 42, 1063–1067.

Thellenberg, C., Malmer, B., Tavelin, B., et al., 2003. Second primary cancer in men with prostate cancer: an increased risk of male breast cancer, J. Urol. 169, 1345–1348.

UNSCEAR, 2001. Hereditary Effects of Radiations: Scientific Annex of UNSCEAR 2001 report to the General Assembly. UNSCEAR, Vienna.

US NRC, 1988. A Regulatory Analysis on Emergency Preparedness for Fuel Cycle and Other Radioactive Material Licensees. US Nuclear Power Plants. NUREG-1140. US Nuclear Regulatory Commission, Washington, DC.

US NRC, 2002. Consolidated Guidance about Material Licenses, Program-Specific Guidance about Medical Use Licenses. NUREG-1556. US Nuclear Regulatory Commission. U-1–U-27.

Welle, G.J., Quinn, K., 1992. Pulmonary embolization of iodine-125 implants, AJR Am. J. Roentgenol. 159, 218.

Woolsey, J., Miller, N., Theodorescu, D., 2003. Permanent interstitial brachytherapy for prostate cancer: a current review. World J. Urol.

Yumoto, Y., Hanafusa, T., Nagamatsu, T., et al., 2000. Experimental incineration of low level radioactive samples, Health Phys. 79 (Suppl. 2), S25–S32.

Yurdakul, G., de Reijke, T.M., Blank, L.E., et al., 2003. Rectal squamous cell carcinoma 11 years after brachytherapy for carcinoma of the prostate, J. Urol. 169, 280.

Zelefsky, M.J., Whitmore, W.F., 1997. Long term results of retropublic permanent ¹²⁵I implantation of the prostate for clinically localized prostate cancer, J. Urol. 158, 23–30.

Zelefsky, M.J., Hollister, T., Raben, A., et al., 2000. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent ¹²⁵I prostate implantation for patients with localized prostate cancer, Int. J. Radiat. Oncol. Biol. Phys. 47, 1261–1266.

Zelefsky, M.J., Yamada, Y., Marion, C., Sim, S., Cohen, G., Ben-Porat, L., Silvern, D., Zaider, M., et al., 2003. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy, Int. J. Radiat. Oncol. Biol. Phys. 55, 956–963.